INTRODUCTION
In 1966, Duke-Elder opined that ocular tuberculosis (OTB) should be diagnosed in 'cases of miliary or proliferative lesions in which there is no evidence of other disease liable to cause a granulomatous uveitis and which exhibit tuberculous disease elsewhere, particularly if specific therapy induces a favourable response'. 1 Today, OTB in most cases still remains a presumptive, clinical diagnosis-not too far different from what was first described many years ago as we still do not have an ideal diagnostic test for OTB. In most cases, clinicians may only commit to 'probable' and 'possible' diagnoses of OTB in the presence of clinical signs and supportive investigations, 2 in the absence of other possible causes of uveitis. 3 The purpose of this review is to discuss the three main controversies of OTB today, with respect to the disease terminology, diagnostic challenges and dilemmas in management.
CONTROVERSY NO. 1: TERMINOLOGY OF OTB
The global burden of tuberculosis (TB) is still significant today-an estimated 9 million people with active TB, and a third of the world's population with suspected Mycobacterium tuberculosis (MTB) infection. 4 The WHO reported an increasing number of TB infections in both the low/ middle-income and high-income countries due to multidrug-resistant TB, HIV and global migration. 5 This globalisation and resurgence of TB means that ophthalmologists now see a spectrum of disease: from eyes with obvious clinical OTB to mildly symptomatic patients with uveitis associated with an occult TB infection. [5] [6] [7] However, the heterogeneous definition of OTB and the terminology of 'probable' and 'possible' OTB, which have resulted from the lack of an ideal specific test, may have contributed to the variability in reported prevalence of OTB. For example, the reported incidence of ocular involvement in patients with TB infection ranges from 1.4% in a sanatorium study by Donahue in 1967 to 16% in a highly endemic population in Saudi Arabia and 18% in patients with culture-proven TB in Spain. 8 On the other hand, some studies report OTB as a percentage of all uveitis cases, which may range from 7% to 10.5%. 8 Cross-sectional studies estimate a range from 1% to 4% areas with low TB endemicity, such as the USA, Europe and Japan, to 10%-26% in highly endemic regions such as India and Saudi Arabia. 9 Even the reports of OTB prevalence within a country vary according to region, from <1% in tertiary referral clinics to 10% or more in highly endemic regions of North America. 2 In Europe, the percentage of patients with OTB from endemic countries ranges from 13.5% to 85%. 10 However, it is unclear from many of these studies on how the diagnosis of OTB was defined and if they included 'probable' or 'possible' diagnoses. Thus, we are uncertain if the wide variability of OTB reported is true or a result of a lack of standardisation of the definition of the disease.
Therefore, there remains an important unmet need to standardise the terminology used for OTB diagnosis and a consensus among clinicians when reporting the prevalence of OTB-before we can truly appreciate the burden of this disease and compare study populations.
CONTROVERSY NO. 2: DIAGNOSIS OF OTB
The controversy in the diagnosis of OTB may stem from the uncertainty in the actual disease pathogeneses: Is this condition a TB infection of the eye or inflammation associated with a remote or systemic TB infection? 11 To prove the first hypothesis, MTB has to be detected from within the eye. However, detection of acid-fast bacilli (AFB) with Ziehl-Neelsen or auramine-rhodamine stains has a low yield from the aqueous or vitreous. 12 Cultures have an even lower yield, are laborious and may take 6-8 weeks. 13 It is yet more rare to obtain histopathologic evidence of necrotising granulomatous inflammation from an ocular biopsy, which would need to be sufficiently large to support the diagnosis of OTB 14 15 in the presence of AFB or supporting evidence of MTB DNA. 16 17 The above techniques which attempt to isolate MTB from ocular samples may be challenged by the low sample volume and the paucibacillary nature of the disease. 18 Alternatively, the poor positive yield of these results may be explained by the second hypothesis of OTB being an immune-mediated mechanism of inflammation. 19 Nucleic acid amplification tests may be another method of detecting MTB DNA from the eye, but it lacks comparisons to culture as a gold standard 20 and is unable to distinguish active infection from latent. Furthermore, these tests are affected by the volume of the sample, method of DNA extraction, number of targets used for amplification and presence of inhibitors in the sample. 18 The specificities of these tests are high but sensitivities have been variable, that is, PCR: 33%-67%, 21 quantitative real-time PCR: 57%, 22 multiplex PCR: 78% and loop-mediated isothermal amplification test: 86%. 23 Moreover, all these tests usually require specialised and/or expensive laboratory equipment or reagents.
On the other hand, a patient presenting with uveitis and some evidence of pulmonary or systemic TB may not actually have OTB. 10 The chest X-ray (CXR), which images the most common primary TB infection site, is normal in up to 70% of the patients with OTB. 16 Radiological signs such as hilar lymphadenopathy and parenchymal scarring may not be specific of pulmonary TB. 24 In cases where the CXR is inconclusive, more advanced radiological techniques such as CT or positron emission tomography scans may be useful to discern hilar, parenchymal or pleural disease. [25] [26] [27] Immunological tests such as the tuberculin skin test (TST) lack specificity and do not distinguish latent from active TB disease, 28 29 with reported sensitivity: 71% (95% CI 65% to 74%) and specificity 66% (95% CI 46% to 86%). 30 Newer blood tests such as the interferon-γ release assays (IGRA) that include the QuantiFERON-Gold In-Tube (Cellestis, Carnegie, Australia) or T-SPOT.TB (Oxford Immunotec, Abingdon, UK) have gained popularity in recent years. [31] [32] [33] [34] The main advantage of IGRA is that it is an objective, reproducible blood test that requires only one visit. 35 However, its disadvantages are the inability to distinguish latent from active infection, a higher cost, with time and temperaturesensitive sample processing. 36 While evidence suggests that IGRA have better sensitivities and specificities compared with the TST, there is currently no consensus on its use (single vs combination with TST or CXR) with regard to the screening and diagnosis of TB. [37] [38] [39] False-positive results are often a result of the low positive predictive value of the diagnostic test in areas that have very low pretest probability of disease. 40 In other words, a negative test effectively rules out TB, but false positives are common; 40 for example, in sarcoidosis where elevated interferon-γ levels are seen in some patients with uveitis. 41 Due to the difficulty in its diagnosis, the investigative approach to OTB is heterogeneous worldwide. 42 For example, TST may be preferred over IGRA in low/middle-income countries, and CT chest may be more commonly ordered in high-income countries to detect subtle pulmonary involvement. 42 Cost-effective analyses have suggested using IGRA in high-risk groups, the higher unit cost largely compensated by cost savings through more targeted performance of CXRs, follow-up and chemoprevention, 43 44 especially in migrant populations and patients on haemodialysis and tumour necrosis factor alpha (TNF-α) blockade. [45] [46] [47] In our own study, we found that combination of an IGRA with a TST had the most costeffective model in the diagnosis of TB. 48 While there is currently no consensus on the clinical approach to the diagnosis of OTB, most clinicians agree that careful ocular evaluation provides an important role. The identification of clinical signs such as broad-based synechiae, retinal vasculitis, multifocal choroiditis and serpiginoid choroiditis may be suggestive in some endemic regions, 49 50 although not as useful in non-endemic regions. 51 52 Nonetheless, the protean nature of OTB infection means that patients may present with a whole spectrum of clinical signs, that is, from granuloma, nodular scleritis and interstitial keratitis in the anterior segment to caseating granulomas in the ciliary body or choroidal tubercles in the posterior segment. 53 A suggested clinical approach involves first identifying these suggestive clinical signs, followed by a step-ladder approach to confirm the diagnosis: (1) after the exclusion of other causes of uveitis, (2) the results of TST, IGRA, CXR or CT chest and (3) biopsy with molecular testing would be considered, before confirming a 'definite' case of OTB. 54 
CONTROVERSY NO. 3: TREATMENT OF OTB
There are currently no guidelines for the commencement or duration of anti-TB therapy (ATT) in patients with OTB. 55 Whether OTB is a true infection of the eye or related to a systemic occult TB infection, at least it is known that ATT decreases the lifetime risk of developing active TB by 80%-90% in those with latent TB infections. 30 Thus, it is believed that ATT could help eliminate the MTB inciting ocular inflammation either from within the eye or elsewhere in the body. [56] [57] [58] [59] Once the risks and benefits of initiating OTB have been weighed, the typical treatment regimen is to begin a combination of both systemic corticosteroids and ATT, typically a combination of isoniazid, rifampin, ethambutol and pyrazinamide. Some authors also recommend the consultation of an infectious disease specialist in the management, as many of these drugs may evoke allergic reactions or incur intolerable side effects. 60 As there are currently no guidelines on ATT duration, most patients with OTB receive 6 months of the standard regimen. 61 However, a recent survey among ophthalmologists revealed a large variability in the duration of ATT or when therapy is discontinued in non-responders. 62 One study even suggested that a longer duration of more than 9 months ATT is required for the treatment of OTB. 55 To reduce the risk of overtreating patients with uveitis and false-positive TB results, 63 others have suggested raising the threshold of cut-off values such as that used in TST or IGRA before initiating ATT. 64 It has also been recently suggested that some patients with higher IGRA responded with better treatment success. 65 However, it is important to note that in many of these studies, the definition of clinical and treatment outcomes was inconsistent-largely due again to the lack of an exact definition of OTB, variation in duration and type of ATT and the variable use of concomitant corticosteroid therapy. 65 Moreover, a lack of treatment response may be due to drug resistance, which is reported that up to 40% of patients with definite OTB, especially in patients originating from endemic countries. 66 Therefore, a consensus is required to guide clinicians in the treatment and duration of OTB to avoid unnecessary treatment, overexposure to side effects and to the reduce the risk of introducing drug resistance. 67 
CONCLUSION
Recent advances in diagnostic tools for OTB such as molecular techniques for MTB DNA detection and immunological tests such as IGRA have improved the specificity of making this diagnosis. 68 69 However, the clinical diagnosis of OTB remains a complex issue, as these investigations are mainly adjunctive and complementary, while the clinical manifestations of OTB are protean. 53 The current review highlights the three main issues, which suggests that our approach to tackling this disease requires a collaboration from ophthalmologists around the world to establish (1) a consensus on the terminology and thus accurate reporting of OTB to allow comparisons among studies; (2) suggested guidelines on first-line investigations to use for endemic versus non-endemic regions and (3) guidance on treatment specifically for OTB in terms of systemic anti-TB and corticosteroid therapy.
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